What You Should Know:
– Lunit (KRX:328130.KQ), a provider of AI-powered cancer diagnostics and therapeutics solutions, announced today two significant commercial agreements that mark its continued European expansion.
– These strategic deals will bring Lunit’s AI-powered cancer screening solution to healthcare providers in France and Portugal, aiding in the fight against cancer.
TeleDiag and Lunit Partner to Improve Lung Cancer Detection in France
Lunit has partnered with TeleDiag, France’s largest teleradiology group, to supply its AI-powered chest X-ray analysis solution, Lunit INSIGHT CXR. This CE-marked solution is designed to detect ten of the most common lung abnormalities, including lung cancer, with high accuracy.
TeleDiag boasts a vast network of over 600 radiologists serving more than 300 medical practices. Annually, they screen over 600,000 patients. The incorporation of Lunit INSIGHT CXR into their workflow has the potential to significantly improve lung disease detection accuracy and effectiveness across the French healthcare system.
TeleDiag selected Lunit after a rigorous evaluation of various AI solutions for chest X-rays. Lunit INSIGHT CXR stood out due to its exceptional technical performance and ability to identify a wider range of findings.
LPCC Selects Lunit for AI-driven Mammography Analysis in Portugal
In a separate agreement, Lunit has partnered with the Portuguese League Against Cancer (LPCC) to deliver its FDA-cleared and CE-marked AI solution for mammography analysis, Lunit INSIGHT MMG. The central region branch of LPCC plans to leverage this technology to analyze an estimated 100,000 mammograms annually over the next three years.
Founded in 1941, LPCC is a crucial non-profit organization overseeing the Portuguese National Breast Cancer Screening Program. Their decision to choose Lunit’s solution came after a comprehensive internal validation process using their own population screening data. During this process, Lunit INSIGHT MMG demonstrated exceptional performance.
